Human TACI/TNFRSF13B enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.16 pg/ml (50 μl)；1.13 pg/ml (10 μl)； |
| Standard Curve Range | 0.69~500 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0081 | 0.0079 | 0.0080 | |
| 0.69 | 0.0137 | 0.0125 | 0.0131 | 0.0051 |
| 2.06 | 0.0251 | 0.0244 | 0.0248 | 0.0168 |
| 6.17 | 0.0638 | 0.0618 | 0.0628 | 0.0548 |
| 18.52 | 0.1835 | 0.1750 | 0.1793 | 0.1713 |
| 55.56 | 0.5140 | 0.5085 | 0.5113 | 0.5033 |
| 166.67 | 1.4020 | 1.3400 | 1.3710 | 1.3630 |
| 500.00 | 3.0470 | 3.0110 | 3.0290 | 3.0210 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 10.4 | 48.7 | 168.2 | 9.8 | 47.0 | 158.1 |
| Standard Deviation | 0.3 | 1.1 | 8.1 | 0.7 | 1.9 | 10.8 |
| Coefficient of Variation(%) | 2.7 | 2.3 | 4.8 | 6.7 | 4.0 | 6.9 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty-two times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human TACI/TNFRSF13B into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 90% to 120% with an overall mean recovery of 114%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 79.81-196.15 | 100 | 112.17 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of human TACI/TNFRSF13B in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: TACI/TNFRSF13B
TACI, transmembrane activator and CAML-interactor, is a member of the TNF receptor superfamily. TACI is a type III membrane protein with an extracellular
N‑terminus in the absence of a cleaved signal sequence. The extracellular region of TACI contains two cysteine rich domains. Within the TNFRSF, it shares the highest homology with BCMA. TACI and BCMA have both been shown to bind APRIL and BAFF, members of the TNF ligand superfamily. TACI is expressed on the cell surface of B cells and activated, but not resting, T cells. Analogous to BCMA, data suggests that TACI may play an important role in B cell development, function and regulation. Human TACI is a 293 amino acid (aa) protein consisting of a 166 aa extracellular domain, a 20 aa transmembrane domain, and a 107 aa intracellular domain. Human and mouse TACI share 54% amino acid identity.
